First description of a type v osteogenesis imperfecta clinical case with severe skeletal deformities caused by a mutation p.119C> T in IFITM5 gene in Russia

Osteogenesis imperfecta (OI) is a hereditary connective tissue disorder. Main clinical manifestations include recurring pathological fractures and progressive skeletal deformation. Five types of OI are distinguished based on clinical symptoms. In most cases, the disease is caused by mutations in the COL1A1 and COL1A2 genes, leading to a defect of type 1 collagen synthesis, which is the main component of the bone matrix. Up to 5% of patients with OI have a mutation in IFITM5 gene, which leads to the development of OI type V. Approximately 150 cases of the OI type V are described in the literature, and mutation c.-14C> T in IFITM5 gene is found in most of the cases. Only 5 patients have a c.119C> T: p.S40L.mutation.

Pathogenesis of OI type V is not fully understood. It is assumed that mutations in the IFITM5 gene cause impaired osteoblastogenesis, decreased bone mineral density and multiple low-traumatic fractures. There is probably a phenotype-genotypic correlation in cases with different mutations of the IFITM5. However, it is currently difficult to assess the relationship in view of the variability of the characters and the low prevalence of the OI type V.

We present the first description in Russia of the clinical case of an adult patient with OI type V due to a rare mutation p.119C> T: p.S40L in the IFITM5 gene.

osteogenesis imperfecta, IFITM5, BRIL, teriparatide, fracture

1. Steiner RD, Basel D. COL1A1/2 Osteogenesis Imperfecta. In: Adam MP, Ardinger HH, Pagon RA, et al, editors. GeneReviews. Seattle: University of Washington, Seattle; 1993-2019.

2. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979;16(2):101-116. doi: https://doi.org/10.1136/jmg.16.2.101

3. Glorieux FH, Rauch F, Plotkin H, et al. Type V osteogenesis imperfecta: a new form of brittle bone disease. J Bone Miner Res. 2000;15(9):1650-1658. doi: https://doi.org/10.1359/jbmr.2000.15.9.1650

4. Van Dijk FS, Sillence DO. Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment. Am J Med Genet A. 2014;164A(6):1470-1481. doi: https://doi.org/10.1002/ajmg.a.36545

5. Shapiro JR. Clinical and Genetic Classification of Osteogenesis Imperfecta and Epidemiology. 2014:15-22. doi: https://doi.org/10.1016/b978-0-12-397165-4.00002-2

6. Малыгина А.А., Гребенникова Т.А., Тюльпаков А.Н., Белая Ж.Е. Несовершенный остеогенез как причина летального исхода. // Остеопороз и остеопатии. — 2018. — Т. 21. — №1. — С. 23-27. [Malygina AA, Grebennikova TA, Tiulpakov AN, Belaya ZE. Osteogenesis imperfecta as a cause of death. Osteoporosis and bone diseases. 2018;21(1):23-27. (In Russ.)] doi: https://doi.org/10.14341/osteo9733

7. Bonafe L, Cormier-Daire V, Hall C, et al. Nosology and classification of genetic skeletal disorders: 2015 revision. Am J Med Genet A. 2015;167A(12):2869-2892. doi: https://doi.org/10.1002/ajmg.a.37365

8. Яхяева Г.Т., Маргиева Т.В., Намазова-Баранова Л.С., и др. V тип несовершенного остеогенеза. Наблюдение редкого случая. // Педиатрическая фармакология. — 2015. — Т. 12. — №1. — С. 79-84. [Yakhyayeva GT, Margieva TV, Namazova-Baranova LS, et al. Clinical Case of Rare Type V Osteogenesis Imperfecta. Pediatric pharmacology. 2015;12(1):79-84. (In Russ.)]

9. Cho TJ, Lee KE, Lee SK, et al. A single recurrent mutation in the 5’-UTR of IFITM5 causes osteogenesis imperfecta type V. Am J Hum Genet. 2012;91(2):343-348. doi: https://doi.org/10.1016/j.ajhg.2012.06.005

10. Semler O, Garbes L, Keupp K, et al. A mutation in the 5’-UTR of IFITM5 creates an in-frame start codon and causes autosomal-dominant osteogenesis imperfecta type V with hyperplastic callus. Am J Hum Genet. 2012;91(2):349-357. doi: https://doi.org/10.1016/j.ajhg.2012.06.011

11. Farber CR, Reich A, Barnes AM, et al. A novel IFITM5 mutation in severe atypical osteogenesis imperfecta type VI impairs osteoblast production of pigment epithelium-derived factor. J Bone Miner Res. 2014;29(6):1402-1411. doi: https://doi.org/10.1002/jbmr.2173

12. Guillen-Navarro E, Ballesta-Martinez MJ, Valencia M, et al. Two mutations in IFITM5 causing distinct forms of osteogenesis imperfecta. Am J Med Genet A. 2014;164A(5):1136-1142. doi: https://doi.org/10.1002/ajmg.a.36409

13. Hoyer-Kuhn H, Semler O, Garbes L, et al. A nonclassical IFITM5 mutation located in the coding region causes severe osteogenesis imperfecta with prenatal onset. J Bone Miner Res. 2014;29(6):1387-1391. doi: https://doi.org/10.1002/jbmr.2156

14. Liu Y, Asan, Ma D, et al. Gene mutation spectrum and genotype-phenotype correlation in a cohort of Chinese osteogenesis imperfecta patients revealed by targeted next generation sequencing. Osteoporos Int. 2017;28(10):2985-2995. doi: https://doi.org/10.1007/s00198-017-4143-8

15. Moffatt P, Gaumond MH, Salois P, et al. Bril: a novel bone-specific modulator of mineralization. J Bone Miner Res. 2008;23(9):1497-1508. doi: https://doi.org/10.1359/jbmr.080412

16. Hanagata N, Li X, Morita H, et al. Characterization of the osteoblast-specific transmembrane protein IFITM5 and analysis of IFITM5-deficient mice. J Bone Miner Metab. 2011;29(3):279-290. doi: https://doi.org/10.1007/s00774-010-0221-0

17. Hanagata N, Li X, Morita H, et al. Characterization of the osteoblast-specific transmembrane protein IFITM5 and analysis of IFITM5-deficient mice. J Bone Miner Metab. 2011;29(3):279-290. doi: https://doi.org/10.1007/s00774-010-0221-0

18. Lietman CD, Marom R, Munivez E, et al. A transgenic mouse model of OI type V supports a neomorphic mechanism of the IFITM5 mutation. J Bone Miner Res. 2015;30(3):489-498. doi: https://doi.org/10.1002/jbmr.2363

19. Cao YJ, Wei Z, Zhang H, Zhang ZL. Expanding the Clinical Spectrum of Osteogenesis Imperfecta Type V: 13 Additional Patients and Review. Front Endocrinol (Lausanne). 2019;10:375. doi: https://doi.org/10.3389/fendo.2019.00375

20. Clewemar P, Hailer NP, Hailer Y, et al. Expanding the phenotypic spectrum of osteogenesis imperfecta type V including heterotopic ossification of muscle origins and attachments. Mol Genet Genomic Med. 2019;7(7):e00723. doi: https://doi.org/10.1002/mgg3.723

21. Ward LM, Rauch F, Whyte MP, et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Clin Endocrinol Metab. 2011;96(2):355-364. doi: https://doi.org/10.1210/jc.2010-0636

22. Rauch F, Munns CF, Land C, et al. Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Bone Miner Res. 2009;24(7):1282-1289. doi: https://doi.org/10.1359/jbmr.090213

23. Bradbury LA, Barlow S, Geoghegan F, et al. Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists. Osteoporos Int. 2012;23(1):285-294. doi: https://doi.org/10.1007/s00198-011-1658-2

24. Marini JC, Forlino A, Bachinger HP, et al. Osteogenesis imperfecta. Nat Rev Dis Primers. 2017;3:17052. doi: https://doi.org/10.1038/nrdp.2017.52

25. Shi CG, Zhang Y, Yuan W. Efficacy of Bisphosphonates on Bone Mineral Density and Fracture Rate in Patients With Osteogenesis Imperfecta: A Systematic Review and Meta-analysis. Am J Ther. 2016;23(3):e894-904. doi: https://doi.org/10.1097/MJT.0000000000000236

26. Marom R, Lee YC, Grafe I, Lee B. Pharmacological and biological therapeutic strategies for osteogenesis imperfecta. Am J Med Genet C Semin Med Genet. 2016;172(4):367-383. doi: https://doi.org/10.1002/ajmg.c.31532

27. Semler O, Netzer C, Hoyer-Kuhn H, et al. First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI. J Musculoskelet Neuronal Interact. 2012;12(3):183-188.

28. Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol. 2002;30(3):312-321. doi: https://doi.org/10.1080/01926230252929882

29. Gatti D, Rossini M, Viapiana O, et al. Teriparatide treatment in adult patients with osteogenesis imperfecta type I. Calcif Tissue Int. 2013;93(5):448-452. doi: https://doi.org/10.1007/s00223-013-9770-2

30. Гребенникова Т.А., Трошина В.В., Белая Ж.Е. Маркеры и генетические предикторы остеопороза в рутинной клинической практике. // Consilium Medicum. — 2019. — Т. 21. — №4. — С. 97-102. [Grebennikova TA, Troshina VV, Belaia ZE. Markers and genetic predictors of osteoporosis in routine clinical practice. Consilium Medicum. 2019;21(4):97-102. (In Russ.)] doi: https://doi.org/10.26442/20751753.2019.4.190323

31. Leali PT, Balsano M, Maestretti G, et al. Efficacy of teriparatide vs neridronate in adults with osteogenesis imperfecta type I: a prospective randomized international clinical study. Clin Cases Miner Bone Metab. 2017;14(2):153-156. doi: https://doi.org/10.11138/ccmbm/2017.14.1.153

32. Orwoll ES, Shapiro J, Veith S, et al. Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. J Clin Invest. 2014;124(2):491-498. doi: https://doi.org/10.1172/JCI71101

33. Мамедова Е.О., Гребенникова Т.А., Белая Ж.Е., Рожинская Л.Я. Антитела к склеростину как новая анаболическая терапия остеопороза. // Остеопороз и остеопатии. — 2018. — Т. 21. — №3. — С. 21-29. [Mamedova EO, Grebennikova TA, Belaya ZE, Rozhinskaya LY. Sclerostin antibodies as novel anabolic therapy for osteoporosis. Osteoporosis and bone diseases. 2018;21(3):21-29. (In Russ.)] doi: https://doi.org/10.14341/osteo10127

34. Белова Н.А., Костик М.М., Буклаев Д.С., и др. Федеральные клинические рекомендации (протокол) по оказанию медицинской помощи пациентам с несовершенным остеогенезом. — М.; 2015. [Belova NА, Kostik MM, Buklaev DS, et al. Federal’nye klinicheskie rekomendatsii (protokol) po okazaniyu meditsinskoy pomoshchi patsientam s nesovershennym osteogenezom. Moscow; 2015. (In Russ.)]